Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35100611.
- Also identified by DOI 10.1093/cid/ciac075 and PMC identifier 9383389.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.
Medical subject headings
- COVID-19
- Viral Vaccines